TD Asset Management Inc Lowers Stock Holdings in Sanofi $SNY

TD Asset Management Inc cut its stake in shares of Sanofi (NASDAQ:SNY) by 40.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 279,287 shares of the company’s stock after selling 188,250 shares during the period. TD Asset Management Inc’s holdings in Sanofi were worth $13,492,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the stock. Accent Capital Management LLC acquired a new position in shares of Sanofi during the 1st quarter valued at $29,000. Eastern Bank lifted its holdings in Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after buying an additional 300 shares in the last quarter. Ameritas Advisory Services LLC acquired a new stake in shares of Sanofi in the 2nd quarter valued at about $28,000. Golden State Wealth Management LLC raised its stake in shares of Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after purchasing an additional 545 shares in the last quarter. Finally, Banque Transatlantique SA acquired a new stake in shares of Sanofi in the 1st quarter valued at about $33,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Up 1.2%

Sanofi stock opened at $50.62 on Friday. The firm’s 50 day moving average price is $48.49 and its two-hundred day moving average price is $49.60. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The firm has a market cap of $124.30 billion, a PE ratio of 12.17, a P/E/G ratio of 1.23 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. During the same quarter last year, the company earned $1.73 EPS. The business’s revenue for the quarter was down 7.0% compared to the same quarter last year. On average, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of recent research reports. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $56.00 to $58.00 in a report on Monday, September 8th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.